Back to Watchlist

Evidence memo

BPC-157

Also tracked as: Body protection compound 157, bepecin

Heavy internet interest, mostly preclinical musculoskeletal and wound-healing narratives, and an important regulatory/product-identity boundary.

Safety/regulatory watch Safety watch

Evidence status

Safety/regulatory watch. Evidence level: Safety/regulatory watch.

Claim being evaluated

Whether BPC-157 improves human healing outcomes in controlled trials rather than animal models, anecdotes, or commercial claims.

Why people care

It is one of the most frequently discussed internet peptides for injury recovery, despite the mismatch between enthusiasm and human evidence.

Signal so far

The published signal is mainly preclinical and review-level. Controlled human efficacy evidence remains the missing piece.

Biggest unknown

Human efficacy, long-term safety, product identity, immunogenicity, and whether marketed products resemble studied material.

Safety/regulatory boundary

FDA compounding-safety materials flag peptide-related impurity and characterization issues. No Watchlist copy should be read as sourcing or use guidance.

Watch next

Independent controlled human trials, FDA compounding updates, and stronger analytical standards for any studied product.

Evidence interpretation

High interest, low certainty. The evidence gap is the story.

References